Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study

We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective was to evaluate the optimal dose and safety of XAV...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaborit, Benjamin, Dailly, Eric, Vanhove, Bernard, Josien, Régis, Lacombe, Karine, Dubee, Vincent, Ferre, Virginie, Brouard, Sophie, Ader, Florence, Vibet, Marie-Anne, Le Thuaut, Aurélie, Danger, Richard, Flet, Laurent, Omnes, Anne, Berly, Laetitia, Chiffoleau, Anne, Jobert, Alexandra, Duvaux, Odile, Raffi, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370226/
https://www.ncbi.nlm.nih.gov/pubmed/34181475
http://dx.doi.org/10.1128/AAC.01237-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370226/
https://www.ncbi.nlm.nih.gov/pubmed/34181475
http://dx.doi.org/10.1128/AAC.01237-21

Ejemplares similares